AR042659A1 - Derivados de 4-5 diariltiazoles como ligandos de cb-1 - Google Patents

Derivados de 4-5 diariltiazoles como ligandos de cb-1

Info

Publication number
AR042659A1
AR042659A1 ARP030104798A ARP030104798A AR042659A1 AR 042659 A1 AR042659 A1 AR 042659A1 AR P030104798 A ARP030104798 A AR P030104798A AR P030104798 A ARP030104798 A AR P030104798A AR 042659 A1 AR042659 A1 AR 042659A1
Authority
AR
Argentina
Prior art keywords
group
optionally substituted
alkyl
groups
phenyl
Prior art date
Application number
ARP030104798A
Other languages
English (en)
Inventor
Kristina Berggren
Thomas Elebring
Peter Grasley
Michael Wistermann
Jonas Boestrom
Linda Faellefors
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR042659A1 publication Critical patent/AR042659A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuestos para uso en el tratamiento de obesidad, trastornos psiquiátricos y neurológicos. Composiciones farmacéuticas que los contienen y procesos e intermediarios para prepararlos. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1), y sales, profármacos y solvatos aceptables para uso farmacéutico del mismo, en donde R1 y R2 en forma independiente representan fenilo, tienilo o piridilo cada uno de los cuales está opcionalmente sustituido por uno, dos o tres grupos representados por Z; Z representa un grupo alquilo C1-6, un grupo alcoxi C1-6, hidroxi, halo, trifluorometilo, trifluorometiltio, trifluorometoxi, trifluorometilsulfonilo, nitro, amino, mono o di-alquilamino (C1-3), mono o di-alquilamido (C1-3), alquilsulfonilo C1-3, alcoxicarbonilo C1-3, carboxi, ciano, carbamoílo, mono o di-alquilo (C1-3) carbamoílo, sulfamoilo, acetilo o dos carbonos adyacentes pueden estar sustituidos con el grupo -O-CH2-CH-O-; y fenilo opcionalmente sustituido por uno o más de los siguientes: un grupo alquilo C1-6, trifluorometilo, un grupo alcoxi C1-6, trifluorometoxi, o halo o dos carbonos adyacentes pueden estar sustituidos con el grupo -O-CH-CH2-O-; y R3 representa un grupo -X-Y-NR4R5 en donde R4 y R5 en forma independiente representan un grupo alquilo C1-6 opcionalmente sustituido por un grupo alcoxi C1-6 o trifluorometoxi; un grupo (amino)alquilo C1-4 en donde el amino está opcionalmente sustituido por uno o más grupos alquilo C1-3; un grupo carbocíclico C3-15 no aromático que está opcionalmente sustituido por un grupo alcoxi(C1-3)-alquilo(C1-3); un grupo cicloalquil(C3-12)-alquilo(C1-3); un grupo -(CH2)r(fenil)s en donde r es 0, 1, 2, 3 ó 4, s es 1 cuando r es 0, caso contrario, s es 1 ó 2 y los grupos fenilo están sustituidos opcionalmente en forma independiente por uno, dos o tres grupos representados por Z; naftilo; antracenilo; un grupo heterocíclico saturado de 5 a 8 miembros que contiene un nitrógeno y opcionalmente uno de los siguientes: oxígeno, azufre o un nitrógeno adicional donde el grupo heterocíclico está opcionalmente sustituido por uno o más grupos alquilo C1-3 o bencilo; 1-adamantilmetilo; un grupo -(CH2)t het en donde t es 0, 1, 2, 3 ó 4, y la cadena alquileno está opcionalmente sustituida por uno o más grupos alquilo C1-3 y Het representa un heterociclo aromático opcionalmente sustituido por uno, dos o tres grupos seleccionados entre un grupo alquilo C1-6; un grupo alcoxi C1-6, trifluorometoxi o halo o Het representa un grupo heterocíclico saturado de 5 a 8 miembros que contiene un nitrógeno y opcionalmente uno de los siguientes: oxígeno, azufre o un nitrógeno adicional; donde el grupo heterocíclico está opcionalmente sustituido por uno o más grupos alquilo C1-3, hidroxi o bencilo; o R4 representa H y R5 tiene los valores que se han definido; o R4 y R5 junto con el átomo de nitrógeno al cual están unidos representan un grupo heterocíclico saturado de 5 a 8 miembros que contiene un nitrógeno y opcionalmente uno de los siguientes: oxígeno, azufre o un nitrógeno adicional; donde el grupo heterocíclico está opcionalmente sustituido por uno o más grupos alquilo C1-3, hidroxi o bencilo; X es CO o SO2; Y está ausente o representa NH opcionalmente sustituido por un grupo alquilo C1-3; con la salvedad de que R1 y R2 no representan ambos 4-metoxifenilo y la salvedad de que cuando R1 representa fenilo y R2 representa fenilo o 4-fluorofenilo, X es CO e Y está ausente entonces el grupo NR4R5 no representa metil-[2-[1-(fenilmetil)-4-piperidinil]etil]amino, metilpiperazino, 2-[1-metil-4-piperidinil]etilamino; o [2-[1-(fenilmetil)-4-piperidinil]etil]amino.
ARP030104798A 2002-12-24 2003-12-22 Derivados de 4-5 diariltiazoles como ligandos de cb-1 AR042659A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0230087.9A GB0230087D0 (en) 2002-12-24 2002-12-24 Therapeutic agents

Publications (1)

Publication Number Publication Date
AR042659A1 true AR042659A1 (es) 2005-06-29

Family

ID=9950372

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104798A AR042659A1 (es) 2002-12-24 2003-12-22 Derivados de 4-5 diariltiazoles como ligandos de cb-1

Country Status (20)

Country Link
US (1) US20060122229A1 (es)
EP (1) EP1581214A1 (es)
JP (1) JP2006516137A (es)
KR (1) KR20050085691A (es)
CN (1) CN1753672A (es)
AR (1) AR042659A1 (es)
AU (1) AU2003290280A1 (es)
BR (1) BR0317703A (es)
CA (1) CA2511603A1 (es)
CO (1) CO5580768A2 (es)
GB (1) GB0230087D0 (es)
IS (1) IS7945A (es)
MX (1) MXPA05006917A (es)
NO (1) NO20052993L (es)
PL (1) PL377295A1 (es)
RU (1) RU2005117789A (es)
TW (1) TW200507839A (es)
UY (1) UY28150A1 (es)
WO (1) WO2004058255A1 (es)
ZA (1) ZA200504953B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415851A (pt) * 2003-10-24 2007-01-02 Solvay Pharm Gmbh utilizações médicas de compostos que apresentam atividade antagonìstica de cb1 e tratamento de combinação envolvendo os referidos compostos
AU2005272815A1 (en) 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of ATP-utilizing enzymes
MX2007004889A (es) * 2004-10-25 2007-09-11 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados.
NZ555320A (en) * 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
WO2006132197A1 (ja) 2005-06-07 2006-12-14 Shionogi & Co., Ltd. I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
FR2894578B1 (fr) * 2005-12-12 2008-02-01 Sanofi Aventis Sa Derives heterocycliques, leur preparation et leur application en therapeutique.
US8017638B2 (en) 2006-03-30 2011-09-13 Shionogi & Co., Ltd. Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
ATE523507T1 (de) 2007-01-04 2011-09-15 Prosidion Ltd Piperidin-gpcr-agonisten
PE20081659A1 (es) 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
EA016507B1 (ru) 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
LT2963031T (lt) 2007-11-30 2019-04-10 Zynerba Pharmaceuticals, Inc. Tetrahidrokanabinolio provaistai, provaistus apimančios tetrahidrokanabinolio kompozicijos ir jų panaudojimo būdai
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010138901A1 (en) * 2009-05-29 2010-12-02 Biogen Idec Ma Inc Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
DE102009038123A1 (de) 2009-08-17 2011-02-24 Aicuris Gmbh & Co. Kg Substituierte (Thiazolyl-carbonyl)imidazolidinone und ihre Verwendung
CA2771278A1 (en) 2009-08-26 2011-03-03 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US9663529B2 (en) 2013-07-02 2017-05-30 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
JP6434968B2 (ja) 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
CN104327065A (zh) * 2014-09-15 2015-02-04 湖南华腾制药有限公司 一种n-甲基-(喹啉-4-基)甲烷胺的制备方法
WO2021207469A1 (en) * 2020-04-09 2021-10-14 Baylor College Of Medicine Novel inhibitors of histone acetyltransferase p300/cbp for cancer therapy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348385A (en) * 1980-11-17 1982-09-07 Mobay Chemical Corporation Flowable pesticides
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
EP0379591B1 (en) * 1988-06-28 1994-01-19 Matsushita Electric Industrial Co., Ltd. Exhaust smoke purifier apparatus
JP3003148B2 (ja) * 1989-01-05 2000-01-24 藤沢薬品工業株式会社 チアゾール化合物、その製造法およびそれを含有する医薬組成物
DE69112917T2 (de) * 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1993010768A1 (de) * 1991-12-05 1993-06-10 Alfatec-Pharma Gmbh Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5468604A (en) * 1992-11-18 1995-11-21 Eastman Kodak Company Photographic dispersion
GB9319129D0 (en) * 1993-09-15 1993-11-03 Dowelanco Ltd Storage and dilution of stable aqueous dispersions
SE9303281D0 (sv) * 1993-10-07 1993-10-07 Astra Ab New formulation
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US6048550A (en) * 1996-10-03 2000-04-11 Chan; Daniel C. F. Hydrophilic microparticles and methods to prepare same
US6127520A (en) * 1997-04-15 2000-10-03 Regents Of The University Of Michigan Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
FR2766368B1 (fr) * 1997-07-24 2000-03-31 Univ Claude Bernard Lyon Procede de preparation de nanocapsules de type vesiculaire, utilisables notamment comme vecteurs colloidaux de principes actifs pharmaceutiques ou autres
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP1205478A4 (en) * 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
CN1254233C (zh) * 2001-08-06 2006-05-03 阿斯特拉曾尼卡有限公司 含有水不溶性的稳定纳米颗粒和赋形剂如中链甘油三酯(mct)的水性分散体
MXPA04002438A (es) * 2001-09-24 2004-06-29 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de pirroll para el tratamiento de la obesidad.
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
AR038966A1 (es) * 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US20060135523A1 (en) * 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
AU2003290280A1 (en) 2004-07-22
CO5580768A2 (es) 2005-11-30
WO2004058255A1 (en) 2004-07-15
PL377295A1 (pl) 2006-01-23
US20060122229A1 (en) 2006-06-08
RU2005117789A (ru) 2006-01-27
UY28150A1 (es) 2004-07-30
ZA200504953B (en) 2006-04-26
JP2006516137A (ja) 2006-06-22
IS7945A (is) 2005-07-19
GB0230087D0 (en) 2003-01-29
MXPA05006917A (es) 2005-08-18
CA2511603A1 (en) 2004-07-15
NO20052993D0 (no) 2005-06-17
BR0317703A (pt) 2005-11-22
CN1753672A (zh) 2006-03-29
TW200507839A (en) 2005-03-01
KR20050085691A (ko) 2005-08-29
NO20052993L (no) 2005-07-25
EP1581214A1 (en) 2005-10-05

Similar Documents

Publication Publication Date Title
AR042659A1 (es) Derivados de 4-5 diariltiazoles como ligandos de cb-1
AR042658A1 (es) Derivados de 1,5-diaril-pirrol-3-carboxamida y su uso como moduladores de receptores canabinoides
AR038044A1 (es) Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
AR044825A1 (es) Derivados de 5,6-diaril-pirazinas-2-carboxamida y -2-sulfonamidas -3-sustituidas como moduladores de cb1
AR073348A1 (es) Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1
AR042273A1 (es) Derivados de pirazol, procedimiento para prepararlos y las composiciones farmaceuticas que los contienen
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR054184A1 (es) Derivados de 1,5 difenilpirazol. procesos de obtencion y composiciones farmaceuticas.
AR047683A1 (es) Pirazoles para el tratamiento de obesidad y trastornos psiquiatricos
AR049487A1 (es) Compuestos de imidazol sustituidos
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
TW200605787A (en) Fungicidal mixtures
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
AR029887A1 (es) Compuestos para el tratamiento de la isquemia, su uso en la fabricacion de medicamentos y composiciones que los contienen
CO6241115A2 (es) Compuestos y composiciones como inhibidores de protein quinasas
AR063707A1 (es) Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
HK1126216A1 (en) 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
RS52978B (en) FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS
AR050251A1 (es) Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
AR054045A1 (es) Compuestos benzoimidazol sustituidos con actividad dual no inhibitoria y mu opioide agonista
AR043038A1 (es) Compuestos de pirazolotriazina y usos de los mismos
EA200802329A1 (ru) Производные триазола ii
BRPI0407695A (pt) compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2

Legal Events

Date Code Title Description
FB Suspension of granting procedure